Joseph McLaughlin, MD | Authors


1628 5TH AVE


PD-L1 As a Predictive Biomarker for Anti-PD-1/Anti-PD-L1 Therapies in Non-Small Cell Lung Cancer

September 02, 2014

Immunotherapies, such as anti-PD-1 and anti-PD-L1 antibodies, offer promising new treatment options for various malignancies including non-small cell lung cancer (NSCLC). With the advent of these immunotherapies, much interest and energy has been focused on developing a companion predictive biomarker.